BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20713874)

  • 1. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
    Yahalom J
    J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse prognosis of bulky disease in good-risk DLBCL.
    Ribera JM
    Lancet Oncol; 2008 May; 9(5):406-7. PubMed ID: 18452849
    [No Abstract]   [Full Text] [Related]  

  • 5. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
    Ueda K; Yokoyama M; Asai H; Koudaira M; Yamada S; Katsube A; Mishima Y; Sakajiri S; Takeuchi K; Saotome T; Terui Y; Takahashi S; Hatake K
    Gan To Kagaku Ryoho; 2010 May; 37(5):853-7. PubMed ID: 20495315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.
    Yu JI; Nam H; Ahn YC; Kim WS; Park K; Kim SJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):507-12. PubMed ID: 20056353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
    Akhtar S; Maghfoor I
    N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
    Copson E
    Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
    Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.
    Morrison VA
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1651-8. PubMed ID: 18925856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
    J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.